Watson L, Moxham J, Fraser P
Lancet. 1980 Jun 21;1(8182):1320-5. doi: 10.1016/s0140-6736(80)91784-5.
Experience is reported of the hydrocortisone suppression test in 140 hypercalcaemic patients, comprising 98 new cases of hyperparathyroidism and 42 cases of non-parathyroid malignant disease. The diagnostic accuracy of the test was compared in 168 patients with that of discriminant analysis, the discriminant functions being derived from plasma inorganic phosphate, alkaline phosphatase, chloride, bicarbonate, and urea, and the erythrocyte sedimentation rate. The hydrocortisone test and discriminant analysis each achieved a diagnostic accuracy of about 93% in 148 patients with either non-parathyroid malignant disease or hyperparathyroidism without osteitis fibrosa. When both tests pointed to the same diagnosis, they were wrong in less than 1% of cases. The hydrocortisone test was not helpful in patients with osteitis fibrosa. Both tests can be performed in any hospital with reliable standard laboratory services. Used in combination they have a high predictive value in distinguishing hypercalcaemia of parathyroid origin from that due to non-parathyroid malignant disease and have not led to errors of clinical importance. They should continue to play a major role in the differential diagnosis of hypercalcaemia until a prompt and reliable service finally establishes parathyroid hormone assay as the definitive laboratory procedure.
报告了对140例高钙血症患者进行氢化可的松抑制试验的经验,其中包括98例甲状旁腺功能亢进新病例和42例非甲状旁腺恶性疾病病例。在168例患者中,将该试验的诊断准确性与判别分析的诊断准确性进行了比较,判别函数来自血浆无机磷、碱性磷酸酶、氯、碳酸氢盐、尿素和红细胞沉降率。在148例患有非甲状旁腺恶性疾病或无纤维性骨炎的甲状旁腺功能亢进患者中,氢化可的松试验和判别分析的诊断准确性均约为93%。当两种试验得出相同诊断时,它们在不到1%的病例中出错。氢化可的松试验对患有纤维性骨炎的患者没有帮助。两种试验在任何具备可靠标准实验室服务的医院都可以进行。联合使用时,它们在区分甲状旁腺源性高钙血症和非甲状旁腺恶性疾病所致高钙血症方面具有很高的预测价值,且未导致具有临床重要性的错误。在快速可靠的服务最终将甲状旁腺激素测定确立为确定性实验室程序之前,它们应继续在高钙血症的鉴别诊断中发挥主要作用。